NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Forecast, Price & News $0.62 -0.01 (-1.46%) (As of 04:32 PM ET) Add Compare Share Share Today's Range$0.61▼$0.6550-Day Range$0.63▼$1.0352-Week Range$0.60▼$5.18Volume3.02 million shsAverage Volume3.81 million shsMarket Capitalization$117.90 millionP/E RatioN/ADividend YieldN/APrice Target$2.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Nektar Therapeutics MarketRank™ ForecastAnalyst RatingHold1.60 Rating ScoreUpside/Downside285.2% Upside$2.40 Price TargetShort InterestBearish5.34% of Shares Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment-0.01Based on 6 Articles This WeekInsider TradingSelling Shares$21,709 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.15) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector584th out of 1,009 stocksPharmaceutical Preparations Industry285th out of 494 stocks 2.8 Analyst's Opinion Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 1.60, and is based on no buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.40, Nektar Therapeutics has a forecasted upside of 285.2% from its current price of $0.62.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.34% of the outstanding shares of Nektar Therapeutics have been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently increased by 5.43%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNektar Therapeutics has received a 60.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Topoisomerase 1 (TOP1) inhibitors", "Clinical research services", and "Peripheral opioid receptor antagonists" products. See details.Environmental SustainabilityThe Environmental Impact score for Nektar Therapeutics is -1.77. Previous Next 1.1 News and Social Media Coverage News SentimentNektar Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,709.00 in company stock.Percentage Held by InsidersOnly 3.38% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions92.30% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nektar Therapeutics (NASDAQ:NKTR) StockNektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.Read More Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Stock News HeadlinesMay 26, 2023 | bizjournals.comHoward Robin seeks another turnaround at NektarMay 26, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Nektar Therapeutics (NASDAQ:NKTR) Issued By Zacks ResearchMay 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 20, 2023 | americanbankingnews.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $14,659.92 in StockMay 18, 2023 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Earns Hold Rating from Analysts at StockNews.comMay 13, 2023 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Receives $2.50 Consensus Target Price from AnalystsMay 12, 2023 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Jefferies Financial GroupMay 11, 2023 | msn.comJefferies Upgrades Nektar Therapeutics (NKTR)May 30, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 10, 2023 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call TranscriptMay 10, 2023 | markets.businessinsider.comJefferies upgrades Nektar Therapeutics (NKTR) to a HoldMay 10, 2023 | markets.businessinsider.comMizuho Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)May 9, 2023 | markets.businessinsider.comNektar Therapeutics Reports First Quarter 2023 Financial ResultsMay 9, 2023 | markets.businessinsider.comNektar Therapeutics Q1 Loss increases, misses estimatesMay 8, 2023 | finance.yahoo.comBiotech Stocks' Q1 Earnings on May 9: NVAX, EBS & MoreMay 2, 2023 | americanbankingnews.comNektar Therapeutics (NKTR) Scheduled to Post Quarterly Earnings on TuesdayApril 28, 2023 | marketwatch.comNektar Regains Rezpegaldesleukin Rights as Eli Lilly Deal Ends >NKTRApril 27, 2023 | finance.yahoo.comNektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical DevelopmentApril 20, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)April 20, 2023 | americanbankingnews.comBrokerages Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $3.08April 18, 2023 | americanbankingnews.comBrokerages Set Nektar Therapeutics (NASDAQ:NKTR) PT at $3.08April 17, 2023 | msn.comNektar stock pops as more than half of San Francisco office loses jobs, new CFO appointedApril 17, 2023 | bizjournals.comNektar Therapeutics to cut San Francisco staff to 55 in major reorganizationApril 17, 2023 | markets.businessinsider.comGoldman Sachs Remains a Sell on Nektar Therapeutics (NKTR)April 17, 2023 | markets.businessinsider.comMizuho Securities Remains a Hold on Nektar Therapeutics (NKTR)April 17, 2023 | finance.yahoo.comNektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring PlanApril 13, 2023 | finance.yahoo.comHere's Why You May Add Nektar (NKTR) Stock to Your PortfolioSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Company Calendar Last Earnings2/28/2023Today5/30/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees740Year Founded1990Price Target and Rating Average Stock Price Forecast$2.40 High Stock Price Forecast$3.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+287.5%Consensus RatingHold Rating Score (0-4)1.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-368,200,000.00 Net Margins-467.00% Pretax Margin-463.59% Return on Equity-84.36% Return on Assets-42.78% Debt Debt-to-Equity RatioN/A Current Ratio8.20 Quick Ratio7.86 Sales & Book Value Annual Sales$92.06 million Price / Sales1.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.32Miscellaneous Outstanding Shares189,240,000Free Float182,839,000Market Cap$117.20 million OptionableOptionable Beta1.09 Social Links Key ExecutivesHoward W. RobinPresident, Chief Executive Officer & DirectorSandra A. GardinerChief Financial & Accounting OfficerMary TagliaferriChief Medical OfficerJonathan ZalevskyChief Research & Development OfficerMark A. WilsonSecretary, Chief Legal Officer & Senior VPKey CompetitorsParatek PharmaceuticalsNASDAQ:PRTKAssembly BiosciencesNASDAQ:ASMBOmerosNASDAQ:OMERChimerixNASDAQ:CMRXEnliven TherapeuticsNASDAQ:ELVNView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 101,421 shares on 5/22/2023Ownership: 0.525%JPMorgan Chase & Co.Bought 41,483 shares on 5/18/2023Ownership: 0.123%New York State Common Retirement FundSold 33,900 shares on 5/18/2023Ownership: 0.043%Geode Capital Management LLCBought 74,365 shares on 5/16/2023Ownership: 1.859%Howard W RobinSold 20,361 sharesTotal: $14,659.92 ($0.72/share)View All Insider TransactionsView All Institutional Transactions NKTR Stock - Frequently Asked Questions Should I buy or sell Nektar Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares. View NKTR analyst ratings or view top-rated stocks. What is Nektar Therapeutics' stock price forecast for 2023? 5 brokerages have issued 12-month price objectives for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's stock price to reach $2.40 in the next year. This suggests a possible upside of 287.5% from the stock's current price. View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts. How have NKTR shares performed in 2023? Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR stock has decreased by 72.6% and is now trading at $0.6193. View the best growth stocks for 2023 here. When is Nektar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our NKTR earnings forecast. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company earned $22.02 million during the quarter, compared to analysts' expectations of $22.21 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 84.36% and a negative net margin of 467.00%. The firm's revenue for the quarter was down 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.79) earnings per share. What ETFs hold Nektar Therapeutics' stock? ETFs with the largest weight of Nektar Therapeutics (NASDAQ:NKTR) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Inspire Small/Mid Cap ETF (ISMD) and What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO? 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY). What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.79%), State Street Corp (3.69%), Pictet Asset Management SA (1.97%), Geode Capital Management LLC (1.86%), Renaissance Technologies LLC (1.59%) and AQR Capital Management LLC (1.45%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $0.62. How much money does Nektar Therapeutics make? Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $117.20 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. How many employees does Nektar Therapeutics have? The company employs 740 workers across the globe. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300. This page (NASDAQ:NKTR) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.